Search

Your search keyword '"de Vries, T"' showing total 1,058 results
Start Over Author "de Vries, T"
1,058 results on '"de Vries, T"'

3. Research Toward Wafer-Scale 3D Integration of InP Membrane Photonics With InP Electronics.

Author

Abdi, S., Nodjiadjim, V., Hersent, R., Riet, M., Mismer, C., de Vries, T., Williams, K. A., and Jiao, Y.

Subjects
OPTICAL receivers, OPTICAL transmitters, SEMICONDUCTOR wafer bonding, SEMICONDUCTOR materials, INDIUM phosphide
Abstract

In this study, we focus on the development of key processes towards wafer-scale 3-dimentional/vertical (3D) integration of Indium-Phosphide (InP) photonic membranes on InP electronics via adhesive bonding. First, we identified the most critical steps and optimized them to achieve high thermal and mechanical compatibility of components for the co-integration process. Next, we developed a strategy for InP-to-InP wafer bonding with high topology tolerance, and introduced hard benzocyclobutene (BCB) anchors to preserve the alignment and BCB thickness uniformity after bonding. The resulting bond layer is homogeneous in terms of physical and mechanical properties. Finally, we developed a novel method to selectively remove the InP substrate from the photonics side via wet etching while protecting the electronics carrier wafer with hermetic multi-layer coatings. The investigation of these key steps is essential for scalable 3D integration of photonics and electronics at ultra short distances (< $15 ~\mu \text{m}$). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. OC 74.4 Prevalence and Predictors of Non-Adherence to Direct Oral Anticoagulant Treatment in Patients with Atrial Fibrillation, a Historical Cohort Study

Author

van der Horst, S., primary, de Vries, T., additional, Chu, G., additional, Bavalia, R., additional, Xiong, H., additional, van de Wiel, K., additional, Mulder, K., additional, van Ballegooijen, H., additional, de Groot, J., additional, Middeldorp, S., additional, Klok, E., additional, Hemels, M., additional, and Huisman, M., additional

Published
2023
Full Text
View/download PDF

23. Determinants of label non-adherence to non-vitamin K oral anticoagulants in patients with newly diagnosed atrial fibrillation

Author

Seelig, J, Trinks-Roerdink, E M, Chu, G, Pisters, R, Theunissen, L J H J, Trines, S A, Pos, L, Kirchhof, C J H J, de Jong, S F A M S, den Hartog, F R, van Alem, A P, Polak, P E, Tieleman, R G, van der Voort, P H, Lenderink, T, Otten, A M, de Jong, J S S G, Gu, Y L, Luermans, J G L M, Kruip, M J H A, Timmer, S A J, de Vries, T A C, Cate, H Ten, Geersing, G J, Rutten, F H, Huisman, M V, Hemels, M E W, Seelig, J, Trinks-Roerdink, E M, Chu, G, Pisters, R, Theunissen, L J H J, Trines, S A, Pos, L, Kirchhof, C J H J, de Jong, S F A M S, den Hartog, F R, van Alem, A P, Polak, P E, Tieleman, R G, van der Voort, P H, Lenderink, T, Otten, A M, de Jong, J S S G, Gu, Y L, Luermans, J G L M, Kruip, M J H A, Timmer, S A J, de Vries, T A C, Cate, H Ten, Geersing, G J, Rutten, F H, Huisman, M V, and Hemels, M E W

Abstract

AIMS: To evaluate the extent and determinants of off-label non-vitamin K oral anticoagulant (NOAC) dosing in newly diagnosed Dutch AF patients.METHODS AND RESULTS: In the DUTCH-AF registry, patients with newly diagnosed AF (<6 months) are prospectively enrolled. Label adherence to NOAC dosing was assessed using the European Medicines Agency labelling. Factors associated with off-label dosing were explored by multivariable logistic regression analyses. From July 2018 to November 2020, 4500 patients were registered. The mean age was 69.6 ± 10.5 years, and 41.5% were female. Of the 3252 patients in which NOAC label adherence could be assessed, underdosing and overdosing were observed in 4.2% and 2.4%, respectively. In 2916 (89.7%) patients with a full-dose NOAC recommendation, 4.6% were underdosed, with a similar distribution between NOACs. Independent determinants (with 95% confidence interval) were higher age [odds ratio (OR): 1.01 per year, 1.01-1.02], lower renal function (OR: 0.96 per ml/min/1.73 m2, 0.92-0.98), lower weight (OR: 0.98 per kg, 0.97-1.00), active malignancy (OR: 2.46, 1.19-5.09), anaemia (OR: 1.73, 1.08-2.76), and concomitant use of antiplatelets (OR: 4.93, 2.57-9.46). In the 336 (10.3%) patients with a reduced dose NOAC recommendation, 22.9% were overdosed, most often with rivaroxaban. Independent determinants were lower age (OR: 0.92 per year, 0.88-0.96) and lower renal function (OR: 0.98 per ml/min/1.73 m2, 0.96-1.00).CONCLUSION: In newly diagnosed Dutch AF patients, off-label dosing of NOACs was seen in only 6.6% of patients, most often underdosing. In this study, determinants of off-label dosing were age, renal function, weight, anaemia, active malignancy, and concomitant use of antiplatelets.

Published
2022

24. Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries

Author

Linschoten, M., Uijl, A., Schut, A., Jakob, C. E. M., Romao, L. R., Bell, R. M., McFarlane, E., Stecher, M., Zondag, A. G. M., van Iperen, E. P. A., Hermans-van Ast, J. F., Lea, N. C., Schaap, J., Jewbali, L. S., Smits, P. C., Patel, R. S., Aujayeb, A., van Smeden, M., Siebelink, H. J., Williams, S., Pilgram, L., Tieleman, R. G., Williams, B., Asselbergs, F. W., Al-Ali, A. K., Al-Muhanna, F. A., Al-Rubaish, A. M., Al-Windy, N. Y. Y., Alkhalil, M., Almubarak, Y. A., Al Nafie, A. N., Al Shahrani, M., Al Shehri, A. M., Anning, C., Anthonio, R. L., Badings, E. A., Ball, C., Van Beek, E. A., Ten Berg, J. M., Von Bergwelt-Baildon, M., Bianco, M., Blagova, O., V, Bleijendaal, H., Bor, W. L., Borgmann, S., van Boxem, A. J. M., van den Brink, F. S., Bucciarelli-Ducci, C., Van Bussel, B. C. T., Byrom-Goulthorp, R., Captur, G., Caputo, M., Charlotte, N., vom Dahl, J., Dark, P., De Sutter, J., Degenhardt, C., Delsing, C. E., Dolff, S., Dorman, H. G. R., Drost, J. T., Eberwein, L., Emans, M. E., Er, A. G., Ferreira, J. B., Forner, M. J., Friedrichs, A., Gabriel, L., Groenemeijer, B. E., Groenendijk, A. L., Gruener, B., Guggemos, W., Haerkens-Arends, H. E., Hanses, F., Hedayat, B., Heigener, D., van der Heijden, D. J., Hellou, E., Hellwig, K., Henkens, M. T. H. M., Hermanides, R. S., Hermans, W. R. M., van Hessen, M. W. J., Heymans, S. R. B., Hilt, A. D., van der Horst, I. C. C., Hower, M., van Ierssel, S. H., Isberner, N., Jensen, B., Kearney, M. T., Kielstein, J. T., Kietselaer, B. L. J. H., Kochanek, M., Kolk, M. Z. H., Koning, A. M. H., Kopylov, P. Y., Kuijper, A. F. M., Kwakkel-van, E. R. P. J. M., Lanznaster, J., van der Linden, M. M. J. M., van der Lingen, A. C. J., Linssen, G. C. M., Lomas, D., Maarse, M., Magdelijns, F. J. H., Magro, M., Markart, P., Martens, F. M. A. C., Mazzilli, S. G., McCann, G. P., van der Meer, P., Meijs, M. F. L., Merle, U., Messiaen, P., Milovanovic, M., Monraats, P. S., Montagna, L., Moriarty, A., Moss, A. J., Mosterd, A., Nadalin, S., Nattermann, J., Neufang, M., Nierop, P. R., Offerhaus, J. A., Van Ofwegen-Hanekamp, C. E. E., Parker, E., Persoon, A. M., Piepel, C., Pinto, Y. M., Poorhosseini, H., Prasad, S., Raafs, A. G., Raichle, C., Rauschning, D., Redon, J., Reidinga, A. C., Ribeiro, M. I. A., Riedel, C., Rieg, S., Ripley, D. P., Rommele, C., Rothfuss, K., Ruddel, J., Ruthrich, M. M., Salah, R., Saneei, E., Saxena, M., Schellings, D. A. A. M., Scholte, N. T. B., Schubert, J., Seelig, J., Shafiee, A., Shore, A. C., Spinner, C., Stieglitz, S., Strauss, R., Sturkenboom, N. H., Tessitore, E., Thomson, R. J., Timmermans, P. J. R., Tio, R. A., Tjong, F. V. Y., Tometten, L., Trauth, J., Van Craenenbroeck, E. M., van Veen, H. P. A. A., den Uil, C. A., Vehreschild, M. J. G. T., Veldhuis, L., I, Veneman, T., Verschure, D. O., Voigt, I, Walter, L., vande Watering, D. J., de Vries, J. K., vande Wal, R. M. A., Westendorp, I. C. D., Westendorp, P. H. M., Westhoff, T., Weytjens, C., Wierda, E., Wille, K., de With, K., Worm, M., Woudstra, P., Wu, K. W., Zaal, R., Zaman, A. G., van der Zee, P. M., Zijlstra, L. E., Alling, T. E., Ahmed, R., Bayraktar-Verver, E. C. E., van Aken, K., Jimenes, Bermudez F. J., Biole, C. A., Den Boer-Penning, P., Bontje, M., Bos, M., Bosch, L., Broekman, M., Broeyer, F. J. F., de Bruijn, E. A. W., Bruinsma, S., Cardoso, N. M., Cosyns, B., Len, van Da D. H., Dekimpe, E., Domange, J., van Doorn, J. L., van DOorn, P., Dormal, F., Drost, I. M. J., Dunnink, A., van Eck, J. W. M., Elshinawy, K., Gevers, R. M. M., Gognieva, D. G., van der Graaf, M., Grangeon, S., Guclu, A., Habib, A., Haenen, N. A., Hamilton, K., Handgraaf, S., Heidbuchel, H., Hendriks-van Woerden, M., Hessels-Linnemeijer, B. M., Hosseini, K., Huisman, J., Jacobs, T. C., Jansen, S. E., Janssen, A., Jourdan, K., ten Kate, G. L., van Kempen, M. J., Kievit, C. M., Kleikers, P., Knufman, N., van der Kooi, S. E., Koole, B. A. S., Koole, M. A. C., Kui, K. K., Kuipers-Elferink, L., Lemoine, I, Lensink, E., van Marrewijk, V, Meijer, E. J., Melein, A. J., Mesitskaya, D. F., van Nes, C. P. M., Paris, F. M. A., Perrelli, M. G., Pieterse-Rots, A., Pisters, R., Polkerman, B. C., van Poppel, A., Reinders, S., Reitsma, M. J., Ruiter, A. H., Selder, J. L., van der Sluis, A., Sousa, A. I. C., Tajdini, M., Sanchez, Tercedor L., Van de Heyning, C. M., Vial, H., Vlieghe, E., Vonkeman, H. E., Vreugdenhil, P., de Vries, T. A. C., Willems, A. M., Wils, A. M., Zoet-Nugteren, S. K., Linschoten, M., Uijl, A., Schut, A., Jakob, C. E. M., Romao, L. R., Bell, R. M., McFarlane, E., Stecher, M., Zondag, A. G. M., van Iperen, E. P. A., Hermans-van Ast, J. F., Lea, N. C., Schaap, J., Jewbali, L. S., Smits, P. C., Patel, R. S., Aujayeb, A., van Smeden, M., Siebelink, H. J., Williams, S., Pilgram, L., Tieleman, R. G., Williams, B., Asselbergs, F. W., Al-Ali, A. K., Al-Muhanna, F. A., Al-Rubaish, A. M., Al-Windy, N. Y. Y., Alkhalil, M., Almubarak, Y. A., Al Nafie, A. N., Al Shahrani, M., Al Shehri, A. M., Anning, C., Anthonio, R. L., Badings, E. A., Ball, C., Van Beek, E. A., Ten Berg, J. M., Von Bergwelt-Baildon, M., Bianco, M., Blagova, O., V, Bleijendaal, H., Bor, W. L., Borgmann, S., van Boxem, A. J. M., van den Brink, F. S., Bucciarelli-Ducci, C., Van Bussel, B. C. T., Byrom-Goulthorp, R., Captur, G., Caputo, M., Charlotte, N., vom Dahl, J., Dark, P., De Sutter, J., Degenhardt, C., Delsing, C. E., Dolff, S., Dorman, H. G. R., Drost, J. T., Eberwein, L., Emans, M. E., Er, A. G., Ferreira, J. B., Forner, M. J., Friedrichs, A., Gabriel, L., Groenemeijer, B. E., Groenendijk, A. L., Gruener, B., Guggemos, W., Haerkens-Arends, H. E., Hanses, F., Hedayat, B., Heigener, D., van der Heijden, D. J., Hellou, E., Hellwig, K., Henkens, M. T. H. M., Hermanides, R. S., Hermans, W. R. M., van Hessen, M. W. J., Heymans, S. R. B., Hilt, A. D., van der Horst, I. C. C., Hower, M., van Ierssel, S. H., Isberner, N., Jensen, B., Kearney, M. T., Kielstein, J. T., Kietselaer, B. L. J. H., Kochanek, M., Kolk, M. Z. H., Koning, A. M. H., Kopylov, P. Y., Kuijper, A. F. M., Kwakkel-van, E. R. P. J. M., Lanznaster, J., van der Linden, M. M. J. M., van der Lingen, A. C. J., Linssen, G. C. M., Lomas, D., Maarse, M., Magdelijns, F. J. H., Magro, M., Markart, P., Martens, F. M. A. C., Mazzilli, S. G., McCann, G. P., van der Meer, P., Meijs, M. F. L., Merle, U., Messiaen, P., Milovanovic, M., Monraats, P. S., Montagna, L., Moriarty, A., Moss, A. J., Mosterd, A., Nadalin, S., Nattermann, J., Neufang, M., Nierop, P. R., Offerhaus, J. A., Van Ofwegen-Hanekamp, C. E. E., Parker, E., Persoon, A. M., Piepel, C., Pinto, Y. M., Poorhosseini, H., Prasad, S., Raafs, A. G., Raichle, C., Rauschning, D., Redon, J., Reidinga, A. C., Ribeiro, M. I. A., Riedel, C., Rieg, S., Ripley, D. P., Rommele, C., Rothfuss, K., Ruddel, J., Ruthrich, M. M., Salah, R., Saneei, E., Saxena, M., Schellings, D. A. A. M., Scholte, N. T. B., Schubert, J., Seelig, J., Shafiee, A., Shore, A. C., Spinner, C., Stieglitz, S., Strauss, R., Sturkenboom, N. H., Tessitore, E., Thomson, R. J., Timmermans, P. J. R., Tio, R. A., Tjong, F. V. Y., Tometten, L., Trauth, J., Van Craenenbroeck, E. M., van Veen, H. P. A. A., den Uil, C. A., Vehreschild, M. J. G. T., Veldhuis, L., I, Veneman, T., Verschure, D. O., Voigt, I, Walter, L., vande Watering, D. J., de Vries, J. K., vande Wal, R. M. A., Westendorp, I. C. D., Westendorp, P. H. M., Westhoff, T., Weytjens, C., Wierda, E., Wille, K., de With, K., Worm, M., Woudstra, P., Wu, K. W., Zaal, R., Zaman, A. G., van der Zee, P. M., Zijlstra, L. E., Alling, T. E., Ahmed, R., Bayraktar-Verver, E. C. E., van Aken, K., Jimenes, Bermudez F. J., Biole, C. A., Den Boer-Penning, P., Bontje, M., Bos, M., Bosch, L., Broekman, M., Broeyer, F. J. F., de Bruijn, E. A. W., Bruinsma, S., Cardoso, N. M., Cosyns, B., Len, van Da D. H., Dekimpe, E., Domange, J., van Doorn, J. L., van DOorn, P., Dormal, F., Drost, I. M. J., Dunnink, A., van Eck, J. W. M., Elshinawy, K., Gevers, R. M. M., Gognieva, D. G., van der Graaf, M., Grangeon, S., Guclu, A., Habib, A., Haenen, N. A., Hamilton, K., Handgraaf, S., Heidbuchel, H., Hendriks-van Woerden, M., Hessels-Linnemeijer, B. M., Hosseini, K., Huisman, J., Jacobs, T. C., Jansen, S. E., Janssen, A., Jourdan, K., ten Kate, G. L., van Kempen, M. J., Kievit, C. M., Kleikers, P., Knufman, N., van der Kooi, S. E., Koole, B. A. S., Koole, M. A. C., Kui, K. K., Kuipers-Elferink, L., Lemoine, I, Lensink, E., van Marrewijk, V, Meijer, E. J., Melein, A. J., Mesitskaya, D. F., van Nes, C. P. M., Paris, F. M. A., Perrelli, M. G., Pieterse-Rots, A., Pisters, R., Polkerman, B. C., van Poppel, A., Reinders, S., Reitsma, M. J., Ruiter, A. H., Selder, J. L., van der Sluis, A., Sousa, A. I. C., Tajdini, M., Sanchez, Tercedor L., Van de Heyning, C. M., Vial, H., Vlieghe, E., Vonkeman, H. E., Vreugdenhil, P., de Vries, T. A. C., Willems, A. M., Wils, A. M., and Zoet-Nugteren, S. K.

Abstract

Aims Patients with cardiac disease are considered high risk for poor outcomes following hospitalization with COVID-19. The primary aim of this study was to evaluate heterogeneity in associations between various heart disease subtypes and in-hospital mortality. Methods and results We used data from the CAPACITY-COVID registry and LEOSS study. Multivariable Poisson regression models were fitted to assess the association between different types of pre-existing heart disease and in-hospital mortality. A total of 16 511 patients with COVID-19 were included (21.1% aged 66-75 years; 40.2% female) and 31.5% had a history of heart disease. Patients with heart disease were older, predominantly male, and often had other comorbid conditions when compared with those without. Mortality was higher in patients with cardiac disease (29.7%; n= 1545 vs. 15.9%; n= 1797). However, following multivariable adjustment, this difference was not significant [adjusted risk ratio (aRR) 1.08, 95% confidence interval (CI) 1.02-1.15; P = 0.12 (corrected for multiple testing)]. Associations with in-hospital mortality by heart disease subtypes differed considerably, with the strongest association for heart failure (aRR 1.19, 95% CI 1.10-1.30; P <0.018) particularly for severe (New York Heart Association class III/IV) heart failure (aRR 1.41, 95% CI 1.20-1.64; P < 0.018). None of the other heart disease subtypes, including ischaemic heart disease, remained significant after multivariable adjustment. Serious cardiac complications were diagnosed in <1% of patients. Conclusion Considerable heterogeneity exists in the strength of association between heart disease subtypes and in-hospital mortality. Of all patients with heart disease, those with heart failure are at greatest risk of death when hospitalized with COVID-19. Serious cardiac complications are rare during hospitalization. [GRAPHICS] .

Published
2022

25. Determinants of label non-adherence to non-vitamin K oral anticoagulants in patients with newly diagnosed atrial fibrillation

Author

Seelig, J, primary, Trinks-Roerdink, E M, additional, Chu, G, additional, Pisters, R, additional, Theunissen, L J H J, additional, Trines, S A, additional, Pos, L, additional, Kirchhof, C J H J, additional, de Jong, S F A M S, additional, den Hartog, F R, additional, van Alem, A P, additional, Polak, P E, additional, Tieleman, R G, additional, van der Voort, P H, additional, Lenderink, T, additional, Otten, A M, additional, de Jong, J S S G, additional, Gu, Y L, additional, Luermans, J G L M, additional, Kruip, M J H A, additional, Timmer, S A J, additional, de Vries, T A C, additional, Cate, H ten, additional, Geersing, G J, additional, Rutten, F H, additional, Huisman, M V, additional, and Hemels, M E W, additional

Published
2022
Full Text
View/download PDF

27. Properties of Metastasizing and Nonmetastasizing Human Melanoma Cells

Author

van Muijen, G. N. P., Danen, E. H. J., de Vries, T. J., Quax, P. H. A., Verheijen, J. H., Ruiter, D. J., Herfarth, Ch., editor, Senn, H.-J., editor, Baum, M., editor, Diehl, V., editor, Gutzwiller, F., editor, Rajewsky, M. F., editor, Wannenmacher, M., editor, Garbe, Claus, editor, Schmitz, Stefan, editor, and Orfanos, Constantin E., editor

Published
1995
Full Text
View/download PDF

28. Phase angle is associated with sarcopenia and its components in patients with chronic hepatitis c

Author

De Vries, T. Pontello, primary, Vieira, D. Alves, additional, Viana, N. Lopes, additional, Coelho, M.P. Pereira, additional, Soares Vaz de Castro, P. Alves, additional, Bering, T., additional, Kakehasi, A.M., additional, Davidson Correia, M.I. Toulson, additional, Ferreira, G. Aparecida, additional, Bezerra, J.M. Trindade, additional, Rocha, G. Aguiar, additional, and Silva, L. Diniz, additional

Published
2021
Full Text
View/download PDF

31. List of contributors

Author

Ang, W.L., primary, Antony, A., additional, Argurio, P., additional, Arribas, P., additional, Bajraktari, N., additional, Basile, A., additional, Bodzek, M., additional, Bouhadjar, S.I., additional, Cassano, A., additional, Curcio, E., additional, Daal, L., additional, Deowan, S.A., additional, de Vos, F., additional, de Vries, T., additional, Di Profio, G., additional, Drioli, E., additional, Fontananova, E., additional, Frenkel, V.S., additional, García-Payo, M.C., additional, Ghaemi, N., additional, Gil, L., additional, Guclu, S., additional, Hélix-Nielsen, C., additional, Hoinkis, J., additional, Ji, Y., additional, Kallioinen, M., additional, Khayet, M., additional, Koyuncu, I., additional, Lee, M., additional, Leslie, G.L., additional, Li, K., additional, Madaeni, S.S., additional, Mänttäri, M., additional, Mohammad, A.W., additional, Molinari, R., additional, Nyström, M., additional, Palmisano, L., additional, Pasaoglu, M.E., additional, Petrinić, I., additional, Rajabi, H., additional, Rastogi, N.K., additional, Sadr, Seyed M.K., additional, Saroj, Devendra P., additional, Sengur, R., additional, Soons, J., additional, Tng, K.H., additional, Turken, T., additional, Van der Bruggen, B., additional, Wang, Y., additional, and Wu, Z., additional

Published
2015
Full Text
View/download PDF

34. Erratum: Human iPSC-derived hippocampal spheroids: An innovative tool for stratifying Alzheimer disease patient-specific cellular phenotypes and developing therapies (Stem Cell Reports (2020) 15(1) (256–273), (S2213671120301922), (10.1016/j.stemcr.2020.06.001))

Author

Pomeshchik, Y., Klementieva, O., Gil, J., Martinsson, I., Hansen, M. G., de Vries, T., Sancho-Balsells, A., Russ, K., Savchenko, E., Collin, A., Vaz, A. R., Bagnoli, S., Nacmias, B., Rampon, C., Sorbi, S., Brites, D., Marko-Varga, G., Kokaia, Z., Rezeli, M., Gouras, G. K., and Roybon, L.

Subjects
Human iPSC-Derived Hippocampal Spheroids, Alzheimer Disease
Published
2021

35. Improving care for young children with atopic dermatitis

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Koster, E. S., De Vries, T. W., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Koster, E. S., and De Vries, T. W.

Published
2021

43. Contra-indicaties voor DOAC’s bij atriumfibrilleren

Author

de Vries, T. A.C., Hemels, M. E.W., Pisters, R., Jansen, R. W.M.M., de Groot, J. R., Cardiology, and ACS - Heart failure & arrhythmias

Abstract

Sometimes there is doubt as to whether or not anticoagulants should be initiated, and if so which ones, in patients with atrial fibrillation and advanced age, increased frailty, or fall risk, kidney, or liver impairment, alcohol abuse, uncontrolled hypertension, or a history of major bleeding. These subgroups have increased risk of haemorrhage as well as thromboembolism. Treatment with anticoagulants is indicated in the vital elderly, preferably with direct oral anticoagulants as demonstrated by robust data. The available study results for the other subgroups may not be (fully) generalisable to clinical practice. In such patients, a comprehensive risk assessment is therefore advised; as is discussing the pros and cons of (not) using anticoagulants and of both type of anticoagulants. Only in exceptional cases is it justified not to use anticoagulants.

Published
2020

44. From transformation to chronification of migraine : pathophysiological and clinical aspects

Author

Torres-Ferrús, M., Ursitti, F., Alpuente-Ruiz, A., Brunello, F., Chiappino, D., de Vries, T., Di Marco, S., Ferlisi, S., Guerritore, L., Gonzalez-Garcia, N., Gonzalez-Martinez, A., Khutorov, D., Kritsilis, M., Kyrou, A., Makeeva, T., Minguez-Olaondo, A., Pilati, L., Serrien, A., Tsurkalenko, O., Van den Abbeele, D., van Hoogstraten, W. S., Lampl, C., Universitat Autònoma de Barcelona, VHIR Vall d'Hebron Institut de Recerca, Internal Medicine, and Neurosciences

Subjects
medicine.medical_specialty, Neurology, Migraine Disorders, lcsh:Medicine, Neurophysiology, Neuroimaging, Neurological disorder, Review Article, Bioinformatics, Pathophysiology, Epigenesis, Genetic, Transformation, Chronic Migraine, Epidemiology, Genetics, Medicine, Humans, Pathological, Chronic migraine, business.industry, lcsh:R, General Medicine, Biomarker, medicine.disease, Biomarker (cell), Animal models, Anesthesiology and Pain Medicine, Migraine, Risk factors, Chronic Disease, Disease Progression, Neurology (clinical), business
Abstract

Chronic migraine is a neurological disorder characterized by 15 or more headache days per month of which at least 8 days show typical migraine features. The process that describes the development from episodic migraine into chronic migraine is commonly referred to as migraine transformation or chronification. Ample studies have attempted to identify factors associated with migraine transformation from different perspectives. Understanding CM as a pathological brain state with trigeminovascular participation where biological changes occur, we have completed a comprehensive review on the clinical, epidemiological, genetic, molecular, structural, functional, physiological and preclinical evidence available.

Published
2020

47. Anti-migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice

Author

Mulder, I.A., Li, M. (Minghui), de Vries, T., Qin, T., Yanagisawa, T., Sugimoto, K., van den Bogaerdt, A., Danser, A.H.J. (Jan), Wermer, M.J.H. (Marieke), Maagdenberg, A.M.J.M. (Arn), Maassen van den Brink, A. (Antoinette), Ferrari, M.D. (Michel), Ayata, C., Mulder, I.A., Li, M. (Minghui), de Vries, T., Qin, T., Yanagisawa, T., Sugimoto, K., van den Bogaerdt, A., Danser, A.H.J. (Jan), Wermer, M.J.H. (Marieke), Maagdenberg, A.M.J.M. (Arn), Maassen van den Brink, A. (Antoinette), Ferrari, M.D. (Michel), and Ayata, C.

Abstract

Objective: Calcitonin gene–related peptide (CGRP) pathway inhibitors are emerging treatments for migraine. CGRPmediated vasodilation is, however, a critical rescue mechanism in ischemia. We, therefore, investigated whether gepants, small molecule CGRP receptor antagonists, worsen cerebral ischemia. Methods: Middle cerebral artery was occluded for 12 to 60 minutes in mice. We compared infarct risk and volumes, collateral flow, and neurological deficits after pretreat

Published
2020
Full Text
View/download PDF

48. Headache medication and the COVID-19 pandemic

Author

Maassen van den Brink, A. (Antoinette), de Vries, T., Danser, A.H.J. (Jan), Maassen van den Brink, A. (Antoinette), de Vries, T., and Danser, A.H.J. (Jan)

Abstract

The world is currently dominated by the Corona Virus Disease 2019 (COVID-19) pandemic. Besides the obvious concerns about limitation of virus spread and providing the best possible care to infected patients, a concomitant concern has now arisen in view of a putative link between the use of certain drugs, such as Renin-Angiotensin System (RAS) inhibitors and ibuprofen, and an increased risk for COVID-19 infection. We here discuss this concern in relation to headache treatment and conclude that, based on current evidence, there is no reason to abandon treatment of headache patients with RAS inhibitors or ibuprofen.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results